$CNTB Has Two Phase 2 Results Coming This Month. Anyone Else Watching This?

$CNTB is one I’m watching closely this month. They have a drug called rademikibart being tested for asthma and COPD, and two Phase 2 trial results are expected in September. One trial has 160 patients and the other has 159, so we should find out very soon what this drug can actually do. If the results are strong, the company plans to meet with the FDA about moving toward Phase 3. They also reported about $31.5 million in cash and investments, which should be enough to keep the company going for at least another year. Now it really comes down to the results. If both trials deliver, $CNTB could suddenly have a lot more eyes on it.